

## Product datasheet for KN201850BN

# AKT1 Human Gene Knockout Kit (CRISPR)

**Product data:** 

**Product Type:** Knockout Kits (CRISPR)

**Format:** 2 gRNA vectors, 1 mBFP-Neo donor, 1 scramble control

**Donor DNA:** mBFP-Neo

Symbol: AKT1 Locus ID: 207

**Components: KN201850G1**, AKT1 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

KN201850G2, AKT1 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

KN201850BND, donor DNA containing left and right homologous arms and mBFP-Neo

functional cassette.

GE100003, scramble sequence in pCas-Guide vector

**Disclaimer:** These products are manufactured and supplied by OriGene under license from ERS. The kit is

designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the

experimental process.

RefSeq: <u>NM 001014431, NM 001014432, NM 005163</u>

UniProt ID: <u>P31749</u>

Synonyms: AKT; CWS6; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com




### Summary:

This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]

## **Product images:**

#### Donor Vector Edited Chromosome



RFP, Luc, and mBFP will be under native gene promoter